Printer Friendly

MEDIMMUNE ANNOUNCES REVIEW OF MEDI 488 RESEARCH PROGRAM

 Gaithersburg, Md., Jan. 4 /PRNewswire/ -- MedImmune, Inc. (NASDAQ: MEDI) announced that unexpected research results with MEDI 488 have caused its collaborator, Merck & Co., Inc., to initiate a series of new laboratory experiments and an overall review of the program. MEDI 488 is a human monoclonal antibody which is the subject of a collaborative research program between MedImmune and Merck to assess its potential to prevent HIV infection. MedImmune and Merck expect to complete the program review within the next two months and then to decide whether or not to continue the program.
 Due to the genetic variability of the HIV virus and the complexity of the infection in humans, MedImmune continues to believe any expectations for MEDI 488 would remain highly speculative, even if the new series of laboratory experiments warrant continuation of the research program.
 MedImmune, Inc. was formed in 1988 to develop, manufacture and market therapeutics and vaccines for the treatment and prevention of certain infectious diseases and cancers. MedImmune's corporate headquarters are in Gaithersburg, Md.
 -0- 1/4/93
 /CONTACT: David M. Mott, vice president of business development and planning of MedImmune, Inc., 301-417-0770, or Anthony J. Russo, Ph.D. of Noonan/Russo Communications, Inc., 212-979-9180, for MedImmune/
 (MEDI)


CO: MedImmune, Inc. ST: Maryland IN: MTC SU:

TM-WB -- NY077 -- 1463 01/04/93 17:30 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 4, 1993
Words:219
Previous Article:MEDIMMUNE FILES WITH FDA FOR APPROVAL OF NEW DRUG FOR PREVENTION OF CHILDHOOD PNEUMONIA
Next Article:SANTA FE RAILWAY COMPLETES SALE OF KANSAS AND OKLAHOMA BRANCH LINES
Topics:


Related Articles
MEDIMMUNE'S CEO REVIEWS RECENT DEVELOPMENTS
MEDIMMUNE COMMENCES PHASE 1 CLINICAL TRIAL WITH FIRST VACCINE FOR B19 PARVOVIRUS
MEDIMMUNE AND BIOTRANSPLANT FORM STRATEGIC ALLIANCE TO DEVELOP ANTI-REJECTION PRODUCTS FOR TRANSPLANTATION
MEDIMMUNE REPORTS THAT RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN)(RSV-IGIV) IS ON DECEMBER AGENDA FOR REVIEW OF BLOOD PRODUCTS...
MedImmune Announces Presentation of MEDI-493 Phase 1/2 Clinical Results at ICAAC
MedImmune and BioTransplant Announce Plans to Test New Drug for Psoriasis
MedImmune and SmithKline Beecham Form Worldwide Human Papillomavirus Vaccine Alliance
MedImmune Requests Marketing Clearance of MEDI-493
MedImmune and BioTransplant Announce Plans to Test MEDI-507 For Treatment of Graft-Versus-Host Disease; IND Submitted
MedImmune and Medarex Announce Filing of Investigational New Drug Application for Monoclonal Antibody for the Treatment of Lupus.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters